Working… Menu

Hematopoietic Stem Cell Support Versus Insulin in T1D

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01285934
Recruitment Status : Withdrawn (No participant enrolled)
First Posted : January 28, 2011
Last Update Posted : August 21, 2015
University of Sao Paulo General Hospital
Information provided by (Responsible Party):
Richard Burt, MD, Northwestern University

Brief Summary:
Type 1 diabetes mellitus (T1D) results from immune-mediated destruction of insulin-producing islet cells. The loss of islet cells is traditionally treated with insulin therapy and in some cases pancreas or islet cell transplantation. Another approach would be to preserve islet cell mass before it is irreversibly lost. Previous trials using immune suppression within 6 weeks of T1D onset have demonstrated diminished exogenous insulin requirements compared to untreated controls. In our prior phase I non-randomized study, by extending immune suppression to the point of immune ablation / immune reset with autologous HSC support, several patients with new onset T1D have maintained an insulin-free, drug free remissions for more than 4 years. Although these results appear highly promising, it may be argued that our results are mitigated by the documented honeymoon effect following T1D, that is by a normal transient insulin free interval occurring after disease onset in some patients. The goal of this trial is to extend this phase I study of new onset T1D to clarify whether our post transplant insulin free interval is due to treatment intervention (transplant) or a result of a normally occurring "insulin free honeymoon period". Both groups will receive identical change of life style (i.e. diet, exercise) education.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 1 Biological: Autologous Hematopoietic Stem Cell Transplantation Drug: intensive insulin therapy Phase 1 Phase 2

Detailed Description:
Eligible patients will have type 1 diabetes (aged ≥ 18 years old) within five months of disease diagnosis, and a positive antibody to an islet cell autoantigen, and fasting C-peptide > 0.2 nmol/l. Hematopoietic stem cells will be mobilized with cyclophosphamide (2.0 g/m2) and granulocyte colony-stimulating factor (10 g/kg/day) collected from peripheral blood by leukoapheresis and cryopreserved. HSC will injected IV after conditioning with cyclophosphamide (200 mg/kg) divided 50 mg/kg on day -5, -4, -3, -2, and rabbit antithymocyte globulin (4.5 mg/kg) divided 0.5 mg/kg day-5, and 1.0 mg/kg day -4, -3-, -2, -1. Rituxan (500mg) IV will be given on days -6 and +1. The control arm will receive either continuous subcutaneous insulin infusion (CSII) or intensive subcutaneous insulin therapy with multiple insulin injections (at least 4/day) utilizing a long acting background insulin and pre-meal rapid acting insulin. The main outcome measure will be: fasting C-peptide. Other outcome measures will include: daily exogenous insulin requirements, serum levels of hemoglobin A1c, area under the curve (AUC) C-peptide levels during mixed meal tolerance test, islet cell autoantigen antibody titers, and quality of life (QOL) short form 36 (SF-36) questionnaire.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Trial of High Dose Immunosuppression and Autologous Hematopoietic Stem Cell Support Versus Intensive Insulin Therapy in Adults With Early Onset Type I Diabetes Mellitus
Study Start Date : January 2009
Actual Primary Completion Date : August 2015
Actual Study Completion Date : August 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: Hematopoietic Stem Cell Transplantation
Patients who meet eligibility and have completed pre-HSCT testing in section 7.0 (study parameters) may be enrolled in the transplant arm and will undergo an Autologous Hematopoietic Stem Cell Transplantation
Biological: Autologous Hematopoietic Stem Cell Transplantation
All participants randomized to the transplant arm wil undergo Autologous Hematopoietic Stem Cell Transplantation

control arm of intensive insulin therapy
The control arm of intensive insulin therapy (IIT) will enroll all patients who meet eligibility but decline HSCT or whose insurance does not approve payment for HSCT before expiration of eligibility (within 5 months of disease onset)
Drug: intensive insulin therapy
The control arm will be either CSII via an insulin pump or intensive subcutaneous insulin therapy with multiple insulin injections (at least 4/day) utilizing a long acting background insulin and pre-meal rapid acting insulin.
Other Name: IIT

Primary Outcome Measures :
  1. C-peptide [ Time Frame: Every 6 months for 5 years ]
    C-peptide (fasting and every 30 minutes during 2 hour mixed meal tolerance test

Secondary Outcome Measures :
  1. Insulin dose [ Time Frame: 5 years ]
    Insulin dose, recorded as daily insulin dose in IU/Kg/day

  2. Serum levels of hemoglobin A1c [ Time Frame: 5 years ]
  3. Stimulated C-peptide levels during mixed meal tolerance test [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years to 35 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ages 16 to 35 years old
  • A diagnosis of type 1 diabetes by hyperglycemia and at least 1 antibody to islet cell autoantigen: GAD, IAA, ICA, IA-2, or Slc30A8
  • Fasting C-peptide > 0.20 nmol / liter
  • Enrollment within 5 months of T1D diagnosis
  • Eligible patients must be referred to a fertility / reproductive endocrinologist and have written documentation of medical counseling advising patients about the risk of infertility and the possible options of sperm and oocyte banking before enrollment.

Exclusion Criteria:

  • HIV positive
  • Patients in the honeymoon phase not taking insulin
  • Hepatitis A, B, or C positive
  • On corticosteroids or other immune suppressive medications
  • History of diabetic ketoacidosis
  • Ongoing malignancy except localized treated basal cell or squamous skin cancer.
  • History of cardiac disease or congestive heart failure or ventricular tachycardia or abnormal dobutamine cardiac echocardiogram
  • Positive pregnancy test, inability or unwillingness to pursue effective means of birth control, failure to willingly accept or comprehend irreversible sterility as a potential side effect of therapy.
  • Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible.
  • DLCO < 60% of predicted
  • Resting LVEF < 45%
  • Creatinine > 1.5 mg/dl
  • Known hypersensitivity to E Coli derived proteins.
  • Transaminases greater than 2 times normal
  • Positive tuberculosis skin test
  • Any active infection
  • Any co-morbid illness that in the opinion of the investigator would jeopardize the ability of the subject to tolerate the study.
  • Failure to collect at least 2.0 x 106 CD34+ cells/kg
  • History of alcohol or illicit drug abuse
  • Unwilling to be compliant with change in life-style-diet and exercise

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01285934

Sponsors and Collaborators
Northwestern University
University of Sao Paulo General Hospital
Layout table for investigator information
Principal Investigator: Richard Burt, MD Northwestern University
Layout table for additonal information
Responsible Party: Richard Burt, MD, MD, Northwestern University Identifier: NCT01285934    
Other Study ID Numbers: Diabetes2008
First Posted: January 28, 2011    Key Record Dates
Last Update Posted: August 21, 2015
Last Verified: March 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs